19 October 2023 | News
Multi-million dollar investment strengthens in vitro biology capabilities for primary and secondary screening
Piramal Pharma Solutions (PPS), a leading pharmaceutical Contract Development and Manufacturing Organisation (CDMO), has officially announced the launching a world-class high-throughput screening facility that augments existing in vitro biology capabilities at its Drug Discovery Services facility in Ahmedabad. This new expansion significantly increases the primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.
With this expansion, Piramal Pharma Solutions is uniquely positioned to provide its customers with an integrated set of discovery capabilities and leverage a broad range of in vitro screening technology tools to support its extensive portfolio of research services. The goal is to generate data that constitutes a superior data set for customers and increase the company's value as an outsourcing partner.
The benefits of this new investment will result in an improved experience for PPS discovery services customers. Integrating chemistry and biology services under one roof promises to increase the efficiency of the discovery process. To enable this expansion, PPS is recruiting experienced staff with a proven track record in biology services, to complement existing technical and operational expertise.
The new high-throughput screening format allows PPS to evaluate and screen large collections using various assay platform technologies, including TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer)/HTRF (Homogeneous Time -Resolved Fluorescence), Fluorescence Polarization (FP), Absorbance, Luminescence/Electrochemiluminescence (ECL), AlphaScreen, LanthaScreen, Flow Cytometry and High Content Imaging. These platforms will be applicable to a variety of targets, including G protein-coupled receptors (GPCRs) and kinases.